Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

Pascale Massin; Francesco Bandello; Justus G Garweg; Lutz L Hansen; Simon P Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U E K Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf

doi:10.2337/dc10-0493

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

Pascale Massin, Francesco Bandello, Justus G Garweg, Lutz L Hansen, Simon P Harding, Michael Larsen, Paul Mitchell, Dianne Sharp, U E K Wolf-Schnurrbusch, Margarita Gekkieva, Andreas Weichselberger, Sebastian Wolf

Afdeling for Øjensygdomme

664 Citationer (Scopus)

Abstract

The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.

Originalsprog	Engelsk
Tidsskrift	Diabetes Care
Vol/bind	33
Udgave nummer	11
Sider (fra-til)	2399-405
Antal sider	7
ISSN	0149-5992
DOI	https://doi.org/10.2337/dc10-0493
Status	Udgivet - 1 nov. 2010

Adgang til dokumentet

10.2337/dc10-0493

Citationsformater

Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., Weichselberger, A., & Wolf, S. (2010). Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care, 33(11), 2399-405. https://doi.org/10.2337/dc10-0493

Massin, P, Bandello, F, Garweg, JG, Hansen, LL, Harding, SP, Larsen, M, Mitchell, P, Sharp, D, Wolf-Schnurrbusch, UEK, Gekkieva, M, Weichselberger, A & Wolf, S 2010, 'Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study', Diabetes Care, bind 33, nr. 11, s. 2399-405. https://doi.org/10.2337/dc10-0493

@article{e71f8f14365f48818d32b6ad00208e87,

title = "Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study",

abstract = "The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.",

author = "Pascale Massin and Francesco Bandello and Garweg, {Justus G} and Hansen, {Lutz L} and Harding, {Simon P} and Michael Larsen and Paul Mitchell and Dianne Sharp and Wolf-Schnurrbusch, {U E K} and Margarita Gekkieva and Andreas Weichselberger and Sebastian Wolf",

year = "2010",

month = nov,

day = "1",

doi = "10.2337/dc10-0493",

language = "English",

volume = "33",

pages = "2399--405",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "11",

}

TY - JOUR

T1 - Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

AU - Massin, Pascale

AU - Bandello, Francesco

AU - Garweg, Justus G

AU - Hansen, Lutz L

AU - Harding, Simon P

AU - Larsen, Michael

AU - Mitchell, Paul

AU - Sharp, Dianne

AU - Wolf-Schnurrbusch, U E K

AU - Gekkieva, Margarita

AU - Weichselberger, Andreas

AU - Wolf, Sebastian

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.

AB - The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.

U2 - 10.2337/dc10-0493

DO - 10.2337/dc10-0493

M3 - Journal article

C2 - 20980427

SN - 0149-5992

VL - 33

SP - 2399

EP - 2405

JO - Diabetes Care

JF - Diabetes Care

IS - 11

ER -

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater